Kronawitter Desiree, Gooren Louis J, Zollver Hendryk, Oppelt Patricia G, Beckmann Matthias W, Dittrich Ralf, Mueller Andreas
Department of Obstetrics and Gynecology, Erlangen University Hospital, Universitätsstrasse 21-23, D-91054 Erlangen, Germany.
Eur J Endocrinol. 2009 Aug;161(2):363-8. doi: 10.1530/EJE-09-0265. Epub 2009 Jun 4.
It has been reported that hypoactive sexual desire disorder (HSDD) affects one-third of transsexual women (defined as postoperative male-to-female transsexuals) receiving estrogen replacement whose bioavailable androgen levels are lower than in ovulating women and comparable with those in surgically postmenopausal women. The aim of this study was to evaluate the efficacy of transdermal testosterone treatment and of oral dydrogesterone in transsexual women with HSDD receiving estrogens.
Seven transsexual women with HSDD were treated with a testosterone patch and nine transsexual women with HSDD were treated with oral dydrogesterone over 24 weeks. The primary end point was the change in the brief profile of female sexual function (B-PFSF) score. Secondary end points were changes in hormonal parameters and side effect assessments.
A significant increase in total testosterone and free testosterone levels was observed in the group receiving transdermal testosterone. At 24 weeks, there was a significant improvement in the B-PFSF score showing an improvement in sexual desire among transsexual women treated with the testosterone patch, whereas no change in the B-PFSF score was observed in transsexual women treated with oral dydrogesterone. No side effects were reported.
In this pilot study, sexual desire in transsexual women improved significantly after treatment with the testosterone patch, without noticeable side effects.
据报道，性欲减退障碍（HSDD）影响三分之一接受雌激素替代治疗的变性女性（定义为术后男性变女性的变性者），其生物可利用雄激素水平低于排卵女性，与手术绝经后女性相当。本研究的目的是评估经皮睾酮治疗和口服地屈孕酮对接受雌激素治疗的患有HSDD的变性女性的疗效。
7名患有HSDD的变性女性接受了24周的睾酮贴片治疗，9名患有HSDD的变性女性接受了24周的口服地屈孕酮治疗。主要终点是女性性功能简要概况（B-PFSF）评分的变化。次要终点是激素参数的变化和副作用评估。
接受经皮睾酮治疗的组中，总睾酮和游离睾酮水平显著升高。在24周时，接受睾酮贴片治疗的变性女性B-PFSF评分显著改善，表明性欲有所提高，而接受口服地屈孕酮治疗的变性女性B-PFSF评分未观察到变化。未报告副作用情况。
在这项初步研究中，变性女性接受睾酮贴片治疗后性欲显著改善，且无明显副作用。
